Format

Send to

Choose Destination
J Neurol. 2020 Feb 7. doi: 10.1007/s00415-020-09730-6. [Epub ahead of print]

Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease.

Author information

1
Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041, Barcelona, Spain.
2
Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain.
3
Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
4
Autonomous University of Barcelona, Barcelona, Spain.
5
European Huntington's Disease Network (EHDN), Ulm, Germany.
6
University of Naples "Federico II", Naples, Italy.
7
Department of Neuropsychiatry, Charité, Universitätsmedizin, Berlin, Germany.
8
Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo della Sofferenza Research Hospital, San Giovanni Rotondo, Italy.
9
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
10
Department of Neurology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
11
Department of Neurology, Fundación Jimenez Diaz, Madrid, Spain.
12
Neurology Department, Coimbra University Hospital, Coimbra, Portugal.
13
Coimbra Institute for Biomedical Imaging and Translational Research - CIBIT, University of Coimbra, Coimbra, Portugal.
14
SMBNOS Department, Bari Aldo Moro University, Bari, Italy.
15
Hospital Mare de Deu de la Mercè, Barcelona, Spain.
16
Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain.
17
Department of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdańsk, Poland.
18
Department of Neurology, St. Adalbert Hospital, Copernicus, PL, Gdańsk, Poland.
19
Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, 08041, Barcelona, Spain. jkulisevsky@santpau.cat.
20
Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain. jkulisevsky@santpau.cat.
21
Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. jkulisevsky@santpau.cat.
22
Autonomous University of Barcelona, Barcelona, Spain. jkulisevsky@santpau.cat.
23
European Huntington's Disease Network (EHDN), Ulm, Germany. jkulisevsky@santpau.cat.

Abstract

BACKGROUND:

Cognitive impairment is an essential feature of Huntington's disease (HD) and dementia is a predictable outcome in all patients. However, validated instruments to assess global cognitive performance in the field of HD are lacking.

OBJECTIVES:

We aimed to explore the utility of the Parkinson's disease-Cognitive Rating Scale (PD-CRS) for the screening of global cognition in HD.

METHODS:

A multicenter cohort of 132 HD patients at different disease stages and 33 matched healthy controls were classified as having preserved cognition, mild cognitive impairment (HD-MCI) or dementia (HD-Dem) according to the Clinical Dementia Rating and Functional Independence Score. The PD-CRS and the Mini-Mental State Examination were administered. Receiver operating characteristic curve analysis was used to determine optimal cutoffs to differentiate patients according to their cognitive status.

RESULTS:

A PD-CRS cutoff score ≤ 81/82 was optimal to detect HD-MCI (sensitivity = 93%; specificity = 80%; area under the curve (AUC) = 0.940), and ≤ 63/64 was optimal to detect HD-Dem (sensitivity = 90%; specificity = 87%; AUC = 0.933). MMSE scores failed to show robust psychometric properties in this context.

DISCUSSION:

The PD-CRS is a valid and reliable instrument to assess global cognition in HD in routine clinical care and clinical trials.

KEYWORDS:

Cognition; Cognitive assessment; Huntington’s disease; Neuropsychology; Psychometrics

PMID:
32030521
DOI:
10.1007/s00415-020-09730-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center